Evidence map›Paper›PMID 32028653›Full record

ArticleBiomolecules2020

Oral HPV16 Prevalence in Oral Potentially Malignant Disorders and Oral Cavity Cancers.

Kai Dun Tang, Lilian Menezes, Kurt Baeten, Laurence J Walsh, Bernard C S Whitfield, Martin D Batstone, Liz Kenny, Ian H Frazer, Gert C Scheper, Chamindie Punyadeera

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Oral Cancer Screening: Past, Present, and Future.Journal of dental research · 2021
    Review
  16. Identification of HPV16-p16Epigenetics · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Kai Dun TangSaliva & Liquid Biopsy Translational Research Team, The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology and the Translational Research Institute, Queensland, Brisbane QLD 4059, Australia.
Lilian MenezesSaliva & Liquid Biopsy Translational Research Team, The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology and the Translational Research Institute, Queensland, Brisbane QLD 4059, Australia.
Kurt BaetenJanssen Diagnostics, a division of Janssen Pharmaceutical NV, 2340 Beerse, Belgium.
Laurence J WalshThe University of Queensland, School of Dentistry, Herston QLD 4006, Australia.
Bernard C S WhitfieldLogan Hospital Integrated Specialist ENT Service, Metro South Health Service District, Queensland Health, Meadowbrook, QLD 4131, Australia.
Martin D BatstoneThe University of Queensland, Department of Maxillo-Facial Surgery, Royal Brisbane and Women's Hospital, Butterfield St, Herston, QLD 4029, Australia.
Liz KennyThe University of Queensland School of Medicine, Royal Brisbane and Women's Hospital, Brisbane, Central Integrated Regional Cancer Service, Queensland Health, QLD 4029, Australia.
Ian H FrazerFaculty of Medicine, The University of Queensland, Translational Research Institute, Brisbane QLD 4102, Australia.
Gert C ScheperJanssen Vaccines & Prevention BV, 2333CN Leiden, The Netherlands.
Chamindie PunyadeeraSaliva & Liquid Biopsy Translational Research Team, The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology and the Translational Research Institute, Queensland, Brisbane QLD 4059, Australia.
Translational Research Institute · AUThe University of Queensland · AUJanssen (Belgium) · BEJanssen (Netherlands) · NLQueensland Health · AU

Funding

Janssen Biotech NA
6 · The paper itself

Abstract

The role of human papillomavirus type 16 (HPV16) in oral potentially malignant disorders (OPMD) and oral cavity carcinoma (OC) is still under debate. We investigated HPV16 prevalence in unstimulated saliva, oral rinse samples, oral swabs and tumour biopsies collected from OPMD (

Indexed as

AgedAustraliaBiopsyCyclin-Dependent Kinase Inhibitor p16DNA, ViralFemaleGenotypeHuman papillomavirus 16HumansMaleMiddle AgedMouth NeoplasmsObserver VariationOdds RatioPapillomavirus InfectionsPrevalenceCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16DNA, Viralhuman papillomavirusoral cavity canceroral potentially malignant disordersalivaviral load and HPV integration

Identifiers

PMID32028653
PMCPMC7072384
OpenAlexW3003505060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.